
Sign up to save your podcasts
Or
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
4.3
2323 ratings
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
13 Listeners
322 Listeners
98 Listeners
160 Listeners
862 Listeners
496 Listeners
692 Listeners
18 Listeners
272 Listeners
255 Listeners
3,321 Listeners
135 Listeners
1,081 Listeners
7,957 Listeners
186 Listeners
59 Listeners
8 Listeners
416 Listeners
314 Listeners